mRNA-1405

Phase 2RNA therapy

Moderna

mRNA-1405 is one of 6 biologic programs targeting Gastroenteritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastroenteritisRecruiting

GastroenteritisPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Gastroenteritis

#DrugCompanyPhaseTrials

Zofran

Novartis

Approved

8 2

Cipro

Bayer

Approved

—3

Reglan

IIstituto Clinico Humanitas

Mrna-1403

2 5

mRNA-1405

Moderna

Phase 2

1 6

Stool Collect

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Recruiting

Gastroenteritis

NCT05992935

Clinical

Trials by Indication[1]

Gastroenteritis1 trial

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Recruiting· Moderna logo

Moderna·Phase 1/2·NCT05992935·1,405 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for mRNA-1405. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-1405 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-1405. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 2[1]
Company: Moderna

mRNA-1405

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Gastroenteritis1 trial

References

Drug Info

Quick Facts

Related News